PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation
PTC Therapeutics, Inc. (NASDAQ: PTCT) has received the 2023 EURORDIS Black Pearl Company Award for Innovation, recognizing its 25-year commitment to rare disease research and treatment. The award celebrates organizations making significant advancements in the development of therapies for rare diseases.
CEO Stuart W. Peltz highlighted the importance of this recognition as PTC marks its quarter-century serving the rare disease community. The award ceremony is scheduled for February 21 in Brussels, coinciding with Rare Disease Day, which aims to raise awareness about rare diseases globally.
- Award signifies recognition of PTC's contributions to rare disease treatments.
- Celebration of 25 years in the industry may enhance company reputation.
- Highlights commitment to patients with limited treatment options.
- None.
- This award recognizes PTC's 25-year legacy in discovering and delivering novel therapies that address the underlying cause of rare diseases -
SOUTH PLAINFIELD, N.J., Feb. 3, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of 2023 EURORDIS Black Pearl Company Award for Innovation. The Black Pearl Awards recognize and celebrate companies who have undertaken ground-breaking activities to advance rare disease research and medicine development.
"We are honored to accept this award and deeply appreciate the recognition of PTC's commitment to providing access to best-in-class treatments for people living with rare diseases with little to no treatment options," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics. "This award is especially meaningful as we proudly celebrate our 25-year history of serving the rare disease community."
"We offer our hearty congratulations to PTC Therapeutics for winning the EURORDIS Black Pearl Company Award for Innovation," said Michael Wilbur, Chief Operating Officer, EURORDIS.
The EURORDIS Black Pearl Awards ceremony will be held on Feb. 21 in Brussels, Belgium. At the ceremony, EURORDIS also raises awareness for Rare Disease Day, an international campaign launched and coordinated by the organization to empower national rare disease alliances. It is observed on the last day of February each year.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, Instagram, LinkedIn, and Twitter at @PTCBio.
Investors:
Kylie O'Keefe
+1 (908) 300-0691
kokeefe@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-receives-2023-eurordis-black-pearl-company-award-for-innovation-301737933.html
SOURCE PTC Therapeutics, Inc.
FAQ
What is the significance of the 2023 EURORDIS Black Pearl Company Award for PTC?
When is the award ceremony for the EURORDIS Black Pearl Awards?
How long has PTC Therapeutics been focused on rare diseases?
What is the stock symbol for PTC Therapeutics?
